Skip to main content
. 2019 Jan 15;9:1560. doi: 10.3389/fphar.2018.01560

Table 5.

Summary of previous studies for the investigation of the efficacy of third-line eradication therapy for H. pylori infection.

First author [ref. no.]s Year Method VPZ-containing eradication regimen
PPI-containing eradication regimen
Number Regimen Eradication rate Number Regimen Eradication rate
Sugimoto (Sugimoto et al., 2017) 2017 OS ITT 15 VPZ: 20 mg bid
AMX: 500 mg qid
STFX: 100 mg bid
80.0%
Sue (Sue et al., 2018b) 2018 RCT ITT 33 VPZ: 20 mg bid
AMX: 750 mg bid
STFX: 100 mg bid
75.8% 30 LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid
AMX: 750 mg bid
STFX: 100 mg bid
53.3%

All paper to investigate efficacy of third-line vonoprazan-containing eradication therapy up until September 2018 were listed. AMX, amoxicillin; bid, twice daily dosing; EPZ, esomeprazole; ITT, intention to treat analysis; LPZ, lansoprazole; MNZ, metronidazole; PPI, proton pump inhibitor; OS, observational study; qid, four times daily dosing; RCT, randomized control trial; RST, retrospective cohort trial; RPZ, rabeprazole; STFX, sitafloxacin; VPZ, vonoprazan.